March 21, 2018 / 12:10 PM / 6 months ago

BRIEF-Checkpoint Therapeutics Initiates Dose Expansion Trial

March 21 (Reuters) - Checkpoint Therapeutics Inc:

* CHECKPOINT THERAPEUTICS INITIATES DOSE EXPANSION PORTION OF PHASE 1 TRIAL OF ANTI-PD-L1 ANTIBODY CK-301 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below